Zydus Lifesciences Q1 FY27 Revenue Up 22% YoY to ₹8,017 Crore; Net Profit Declines 35.9%
Zydus Lifesciences reported Q1 FY27 revenue of ₹8,017 crore, up 22% YoY. Net profit declined 35.9% to ₹940 crore, with EBITDA margin at 24.1%. Key developments include USFDA priority review for Saroglitazar Magnesium and a JV in Sri Lanka. The company also highlighted its ESG initiatives.
The YoY revenue growth is positive, but the decline in net profit and EBITDA margin suggests a mixed financial performance. Strategic initiatives like the JV and R&D progress are positive long-term indicators, but the short-term financial results moderate the impact.
While revenue saw significant YoY growth, the net profit and EBITDA margin declined, indicating mixed performance. Positive developments in R&D and strategic partnerships were offset by the financial downturn.
Zydus Lifesciences Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported total revenues from operations of ₹80,170 million (₹8,017 crore), a significant increase of 22% year-on-year (YoY). The pharmaceutical business contributed 78% to the total revenue, with India branded formulations showing strong growth and outperforming the market. The North America formulations business also saw sequential growth driven by volume expansion and new launches.
The Consumer Wellness business maintained its dominant market share in key Indian brands and delivered robust performance internationally. The MedTech business continued to enhance its capabilities in focused therapies.
However, the company's EBITDA margin stood at 24.1%, a decrease of 770 basis points YoY. Net profit for the quarter was ₹9,398 million (₹940 crore), a decline of 35.9% YoY. Organic capital expenditure (capex) for the quarter was ₹5,852 million (₹585 crore), and the net debt as of June 30, 2026, was ₹59,041 million (₹5,904 crore).
Key developments include the USFDA granting priority review for Saroglitazar Magnesium's NDA for Primary Biliary Cholangitis and regulatory approval in India for Phase III clinical trials of Desidustat for sickle cell disease. The company also entered into a joint venture with Sunshine Healthcare Lanka Limited to establish a pharmaceutical manufacturing facility in Sri Lanka.
Zydus Lifesciences also highlighted its ESG performance, noting a medium risk category rating and its continued inclusion in the FTSE4Good Index Series for the third consecutive year. The company aims for net water neutrality by 2028 and net carbon neutrality by 2035.
What to do with a filing like this
Zydus Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.